Brokers Offer Predictions for Medtronic FY2026 Earnings

Key Points

• Research analysts at Leerink Partners have reduced their FY2026 earnings estimate for Medtronic to $5.63 per share, slightly down from a previous estimate of $5.64.
• Medtronic's latest quarterly earnings report revealed an EPS of $1.26, surpassing analysts’ expectations, along with a revenue of $8.58 billion for the quarter.
• Several analysts have adjusted their target prices for Medtronic's stock, with Argus raising it to $115.00 and Evercore ISI increasing it to $106.00, while the average rating remains a "Moderate Buy."

Medtronic PLC (NYSE:MDT - Free Report) - Research analysts at Leerink Partnrs reduced their FY2026 earnings estimates for Medtronic in a report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the medical technology company will post earnings of $5.63 per share for the year, down from their previous forecast of $5.64. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic's Q4 2026 earnings at $1.69 EPS and FY2027 earnings at $6.08 EPS.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.

Other analysts have also issued reports about the stock. Argus boosted their target price on shares of Medtronic from $105.00 to $115.00 and gave the company a "buy" rating in a research note on Tuesday, August 26th. Evercore ISI boosted their target price on shares of Medtronic from $103.00 to $106.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Mizuho boosted their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Finally, Sanford C. Bernstein boosted their target price on shares of Medtronic from $97.00 to $98.00 and gave the company an "outperform" rating in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $102.82.

Medtronic Stock Down 1.3%

NYSE MDT opened at $95.29 on Thursday. The firm has a market capitalization of $122.23 billion, a price-to-earnings ratio of 26.25, a PEG ratio of 2.54 and a beta of 0.78. Medtronic has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The company has a fifty day moving average of $93.94 and a two-hundred day moving average of $88.90.

Institutional Trading of Medtronic

Several hedge funds have recently modified their holdings of MDT. 1248 Management LLC purchased a new stake in shares of Medtronic during the first quarter valued at about $26,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic in the 2nd quarter valued at approximately $27,000. Columbia River Financial Group LLC purchased a new position in shares of Medtronic in the 1st quarter valued at approximately $28,000. Twin Tree Management LP purchased a new position in shares of Medtronic in the 1st quarter valued at approximately $29,000. Finally, Activest Wealth Management raised its position in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock valued at $30,000 after purchasing an additional 322 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of the firm's stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company's stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company's stock.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic's dividend payout ratio is 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.